backJoin us for our sixth CLE webinar in the Fundamentals of EU Pharmaceutical Law series, as we discuss the complex and evolving landscape of U.S. tariffs and their implications for EU-based or EU-facing pharmaceutical companies.
Since the beginning of President Trump’s second term, his administration has implemented significant new tariffs and trade-related programs, some of which are subject to judicial challenges before U.S. federal courts. Meanwhile, other countries and trading partners (including the EU) have implemented and/or threatened retaliatory tariffs, while also engaging in negotiations with the United States.
On April 1, 2025, the U.S. Department of Commerce initiated a Section 232 “national security” investigation to determine the effects on national security of imports of pharmaceuticals and pharmaceutical ingredients, and their derivative products. Upon a finding that imports threaten U.S. national security, Commerce can recommend a range of measures to mitigate this threat, including tariffs, quotas, and other restrictions on imports, negotiation of trade agreements, and/or other measures. The direct application of Section 232 remedies combined with the direct and indirect effects of these other tariff regimes may have a significant impact on global pharmaceutical sector supply chains.
For questions, contact Christine Lieber.